Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc., has announced promising results from a new scientific publication titled ‘Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS).’ The study, conducted by Tilray Medical, focused on the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM).
The TOMAS study involved patients with an average age of 52 years and examined the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. Researchers closely analyzed the impact of cannabinoids on health outcomes, including pain levels, sleep quality, and overall quality of life.
Under the guidance of healthcare providers, the study revealed encouraging findings. Patients with fibromyalgia who received cannabinoid treatments experienced significant improvements in pain levels, sleep quality, and overall well-being. Notably, the study also observed a significant decrease in the need for other medications, suggesting that cannabinoids could be a cost-effective treatment option.
These findings have important implications for both the medical and scientific communities. The study highlights the potential of cannabinoids to effectively manage chronic pain and improve the quality of life for individuals suffering from fibromyalgia.
“The findings of this study are encouraging and provide hope for fibromyalgia patients who are seeking effective treatments,” said José Tempero, Tilray’s medical director. Denise Faltischek, chief strategy officer and head of international at Tilray Brands, added, “Tilray’s involvement in this study underscores our unwavering commitment to advancing medical research and unlocking the full therapeutic potential of medical cannabis.”
The TOMAS study and its positive outcomes for fibromyalgia patients emphasize the potential of cannabinoids as a safe and effective treatment option for chronic pain and associated symptoms.
Tilray’s shares traded 2.78% higher at $1.665 per share during the pre-market session on Monday morning following the publication of the study’s findings.
